FluoretiQ
Bristol
About FluoretiQ
FluoretiQ is a medical device company designing simple and effective bacterial detection systems for rapid diagnosis of infection. They developing a new solution that combines proprietary nanomaterials and optical sensing technologies to enable the identification of harmful bacteria in minutes. The company nanotechnology utilizes receptor-mediated sensing and Quantum-enhanced optics for the rapid identification of bacterial infection. FluoretiQ developed NANOPLEXa rapid diagnostic platform that identifies and enumerates bacterial pathogens in less than 15 minutes. The NANOPLEXa ensures that patients receive the most effective antibiotic treatment from the start. Their products easy-to-use, providing clinicians with the data to support accurate-same-day diagnosis and more appropriate antibiotic selection. FlouretiQ was founded in 2017 and is headquartered in Bristol, United Kingdom.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.5M
- Funding stage: Seed
- Last round: Seed (Feb 2022)
- Website: fluoretiq.com
- Phone: 0117 403 4077
Industries & Categories
Health Care, Health Diagnostics, Medical Device, Nanotechnology, Software Engineering
Social Profiles
Canonical: https://fsome.com/organization/fluoretiq-176643 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.